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Summary The relationship between percentage M-protein decrement and survival is assessed in 134 multiple
myeloma patients. The correlation did not achieve statistical significance (P=0.069). Multivariate analysis
using the Cox proportional hazards model, including a number of previously recognised prognostic factors,
showed only percentage M-protein decrement, creatinine and haemoglobin to be significantly correlated with
survival. However, the R'-statistic for each of these variables was low, indicating that their prognostic power
is weak. We conclude that neither the percentage M-protein decrement nor the response derived from it can
be used as an accurate means of assessing the efficacy of treatment in myeloma. Mature survival data alone
should be used for this purpose.
As has been the case with any human malignancy, the
effectiveness of drug therapy for the treatment of human
multiple myeloma has been assessed by response rates and
survival data. In the case of myeloma, excluding those
patients with only light chain disease, a clinical response has
been defined by a decrement of either 50% in the serum
M-protein concentration (Chronic Leukemia-Myeloma Task
Force, 1973) or 75% in the serum M-protein synthetic rate
(Alexanian et al., 1972).
Implicit in the use of response data for monitoring
treatment or the assessment of new therapies is the assump-
tion that there -is a statistically significant correlation
between response and survival. However, we have recently
shown in a large series of myeloma patients treated at our
institution that there was, in fact, no statistically significant
correlation between response and survival when myeloma
patients were stratified by stage (Palmer et al., 1987). This
rather unexpected result led to this retrospective multivariate
analysis of the relationship of serum M-protein decrement to
survival of patients with multiple myeloma.
Methods
Patient selection
This study is a retrospective analysis of 161 patients who
were diagnosed to have multiple myeloma at our institution
between September 1977 and September 1985. We have a
population based cancer registry and are the main referral
centre for a population base of 1 million people. Conse-
quently, the vast majority of multiple myeloma patients from
this population base are seen in consultation and entered on
protocols managed from our centre. These protocols
included the MY-2 and MY-4 programmes of the National
Cancer Institute of Canada. The minimum follow-up time
for any patient was 23 months.
Of the 161 patients, 134 were considered evaluable for this
study and none were lost to follow-up. The 27 non-evaluable
patients included three who were never treated and 24 who
had light chain disease alone. Patients with light chain only
myeloma were excluded from this analysis since unmeasured
catabolism of light chains by the kidney can have a signifi-
cant effect on M-protein decrement (Wochner et al., 1967).
Using the staging system of Durie & Salmon (1975) the
patient population was comprised of 12% with stage I, 38%
with stage II, and 50% with stage III disease. Of the patients
included in this study 80% had IgG myeloma and 20% had
IgA myeloma. The overall objective response rate by the
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Chronic Leukemia-Myeloma Task Force criteria was 53%.
At the time of this analysis 77% of the evaluable patients
were deceased.
For the purposes of this analysis of serum M-protein
decrement, we have excluded patients who did not survive
for 3 months. The serum M-protein decrement in myeloma
patients is presumably a function of the melphalan and
prednisolone drug therapy. Therefore, in order to assess the
effect of decrement on survival some minimum guarantee
time is required to assure that drug therapy has had an
opportunity to be effective in reducing serum M-protein. The
3-month guarantee time was selected, since a recent large
clinical trial has shown that the median time for a 50%
reduction in serum M-protein after oral melphalan/
prednisolone therapy was 89 days (Belch et al., 1988).
Diagnosis and treatment
The diagnosis of multiple myeloma was based on the
standard criteria of a patient exhibiting two of the following
findings: (a) either bone marrow plasmacytosis > 10% or
plasmacytosis in a biopsy of a bone or soft tissue lesion; (b)
detection of a serum and/or urine M-protein; or (c) osteoly-
tic lesions. Treatment was initiated at the time of diagnosis
with oral melphalan (9mgm2day-1) and prednisolone
(50mgb.i.d.) for 4 days every 28 days. If the treatment day
white blood cell count was less than 2.0 x 1091 1 or the
platelet count less than 50 x 1091-1, treatment was delayed
until counts were above these levels. Radiation therapy was
used as indicated for the treatment of painful osteolytic
lesions and spinal cord compression. Supportive care for
pain, infections, anaemia and hypercalcaemia were also
given.
Serum M-protein concentrations were determined by
serum protein electrophoresis and immunofixation. The
percentage decrement value used in this analysis was that
produced by the first line oral melphalan/prednisolone
therapy.
Statistical methods
Actuarial survival curves were generated using the life table
method of Kaplan & Meier (1958) and survival analysis was
performed using the log-rank test (Peto & Peto, 1972). The
single factor and multifactor statistical analyses of potential
prognostic factors were carried out using the Cox pro-
portional hazards model (Cox, 1972) as provided by the
PHGLM program in the statistical analysis system of the
SAS Institute (Horrell, 1986). The PHGLM program gener-
ates the correlation coefficient (R'-Statistic) independent of
sample size.
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Results
The median survival from the time of initiation of therapy
for the 134 patients included in this study was 30 months.
The median survival of the 124 patients surviving longer
than 3 months was 33 months.
Single factor and multivariate analyses were carried out to
determine the prognostic significance of a number of factors
on the survival of the 124 patients who survived longer than
3 months. Table I shows the P-values and the R'-statistic
values generated by the PHGLM program in a single factor
analysis. It is seen that creatinine and haemoglobin were the
only factors reaching statistical significance in the single
factor analysis. Table II shows the data obtained in a
multivariate analysis using the backward option of the
PHGLM procedure. This backward mode of analysis first
creates a model including all of the designated variables and
then removes non-significant variables in a stepwise fashion.
In this analysis, the overall R'-statistic is somewhat analo-
gous to the Pearson correlation coefficient, and the indivi-
dual R'-partial statistics provide a measure of the
contribution of variables independent of the sample size.
This analysis showed that creatinine (P=0.002), percentage
M-protein decrement (P=0.01), and haemoglobin (P=0.05)
were the statistically significant prognostic factors. A value
of 0.125 was obtained for the overall R'-statistic. While
several factors reach statistical significance in both the single
factor and multivariate analyses, the R'-statistic value and
the indivudual R'-partial statistic values are very low and
indicate that these factors, either individually or collectively,
provide little overall prognostic information.
For the purposes of illustration a series of linear regres-
sion analyses were carried out to define the predictive value
of the aforementioned variables on the survival of the 91
deceased patients who had survived longer than 3 months.
Figure 1 shows the scattergraph of M-protein decrement
versus survival for this patient group. The analyses showed
that these six variables contributed only 20% of the variance
of the observed survival, with percentage M-protein decre-
ment (15%) and creatinine (4%) being the major factors.
Again the conclusion reached is that the clinical predictive
value of these factors is minimal.
The percentage M-protein decrement was treated as a
continuous variable in the above analysis while it was treated
as a discontinuous variable by Alexanian et al. (1972) in the
often quoted study. Consequently, we analysed our data in
a similar fashion to Alexanian et al., with four classes of
serum M-protein decrement, namely, 0-50%, 51-75%, 76-
90% and greater than 90%. The survival curves for mye-
loma patients falling into these four classes and who sur-
Table I Single factor analysis for the prognostic
effect of various factors of survival (analysis of the
124 patients who survived longer than 3 months)
Variable P-value R'-statistic
% M-protein decrement 0.069 0.041
Creatinine 0.0003 0.10
Haemoglobin 0.038 0.040
Calcium 0.28 0.00
Ig level at diagnosis 0.24 0.00
Age 0.55 0.00
Table II Multivariate analysis using the Cox pro-
portional hazards model for the prognostic effect
of various factors on survival (analysis of the 124
patients who survived longer than 3 months)
Variable P-value R'-statistic
% M-protein decrement 0.011 -0.077
Creatinine 0.0022 0.099
Haemoglobin 0.049 -0.050
Model x2 =22.92 with 3 d.f. (score stat.),
P=0.0001, R-statistic=0.125.
Test for all variables not in the model, residual
x2=O.15 with 3 d.f., P=0.98.
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Figure 1 Scattergraph of survival (in months) by percentage
reduction of M-protein in deceased patients surviving greater
than 3 months.
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Figure 2 Actuarial survival curves of patients surviving greater
than 3 months. The percentage serum M-protein reduction for
the four groups was 0-50% (A); 51-74% (0); 75-90% ([1);
>90% (0).
vived longer than 3 months are shown in Figure 2. Log rank
analysis showed that these survival curves were not statisti-
cally different (P=0.16). Furthermore, trend analysis of
these survival curves showed that a statistically significant
trend was also not evident (P=0.07). The median survivals
for these four classes was 26, 32, 46, and 39 months,
respectively. The comparable values from the earlier study
(Alexanian et al., 1972) were 13, 19, 31 and 37 months
respectively.
Discussion
While the relationship between survival and response, which
is based largely on serum M-protein decrement, is a central
feature of the myeloma literature, there is surprisingly little
data available which substantiates a strong correlation
between M-protein decrement and survival. The data pre-
sented in this report is to our knowledge the first study of
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the relationship between percentage M-protein decrement,
expressed as a continuous variable, and survival in a large
myeloma patient population. Our data shows that while
there is a statistically significant relationship between
percentage M-protein decrement and survival, the predictive
value of this parameter is negligible in light of the very low
values of the R'-statistic. The linear regression analysis of
data from deceased patients showed that only 15% of the
variance of the observed survival could be attributed to
percentage M-protein decrement. It is important to stress
that it is the predictive value of a prognostic factor, as
reflected in the value of the correlation coefficient, and not
merely the P-value that determines its clinical relevance. In
our opinion this latter point has been almost totally ignored
in assessing the importance of prognostic factors in multiple
myeloma.
The most often cited reference given in support of the
relationship between serum M-protein decrement and survi-
val is the 1972 report of Alexanian et al., in which these
authors concluded that a reduction of 75% or more in the
rate of M-protein production resulted in an increased
median survival over those patients who did not attain this
level of M-protein decrement (Alexanian et al., 1972). This
conclusion was based on a statistical comparison of median
survivals of four groups of patients who had attained
differing degrees of M-protein decrement. No data were
presented on the survival curves of these four groups. The
paired comparisons of components of a four class analysis
which was reported in this study is not currently accepted as
being statistically valid in the absence of data showing that
the four classes as a whole are statistically different. Further-
more, the fact that the patient population studied in this
earlier report had been treated with two different drug
regimens during different time periods, further complicating
the interpretation of the data. Analysis of survival curves
from our patient population, stratified in a similar manner
to that of Alexanian et al. (1972), failed to show a significant
difference by log rank analysis or trend analysis. Conse-
quently, it is our contention that the conclusion subsequently
drawn by other investigators that the 1972 data firmly
establish the relationship between survival and M-protein
decrement is unwarranted.
The weak correlation between survival and M-protein
decrement is not really surprising. For a strong correlation
to exist one must hypothesise that tumour mass is related to
survival and that serum M-protein concentration always
reflects tumour mass. It is this latter point that is highly
questionable. In order for the serum M-protein concent-
ration to always reflect tumour mass we must assume (a)
that the M-protein synthetic rate is similar in all myeloma
plasma cells, (b) that this synthetic rate is independent of
changes in the natural history of the individual tumour, (c)
that this synthetic rate is independent of any host factors,
and (d) that this synthetic rate is independent of chemother-
apy and radiation. We believe these assumptions are rather
unrealistic in the light of what is currently known about the
many factors that can alter the extent of protein production
by affecting the cellular rates of transcription and/or
translation.
In the absence of a currently available curative treatment
in myeloma, one aim of management has been to attempt to
achieve disease stabilisation. It might then appear desirable
to assess the prognostic significance of achieving stabilisa-
tion. However, such an analysis is confounded for the
following reason. Taking the definition of disease stabilisa-
tion to be a variance in the M-protein about the mean of no
more than 10% over a minimum of 4 months, the median
time to achieve stabilisation was 10.1 months in a recent
large NCI-Canada myeloma trial (Belch et al., 1988). That
is, it takes a comparatively long time to achieve stabilisation
(i.e. greater than 10 months in half of all patients), which
introduces an enormous guarantee time. The result of this is
inevitably that if you achieve stabilisation your survival is
better than if you don't or, more succinctly, if you live a
long time, you live a long time. While undeniable, this does
not advance our knowledge.
Whatever the cause of the weak correlation between
survival and therapy-induced M-protein decrement, extreme
care should be used in the importance attached to M-protein
decrement. For instance, the design of future clinical trials of
conventional therapy should not use response or M-protein
decrement for randomisation criteria to determine further
therapy, as has been done in the past (Belch et al., 1988;
Mandell et al., 1987; Cohen et al., 1986). Response as
defined largely by M-protein decrement should not be used
for interim assessment of clinical trials, as has been univer-
sally the case in the myeloma literature since standard
response criteria were established for myeloma (Chronic
Leukemia-Myeloma Task Force, 1973; Salmon et al., 1982).
The absence of a treatment-induced serum M-protein decre-
ment should not be used as the sole basis for terminating
existing therapy in favour of an alternative therapy. Finally,
in the light of our data, it is extremely important that the
effectiveness of the very aggressive and toxic first-line thera-
pies currently being evaluated for myeloma be assessed by
survival data alone. Hopefully, the M-protein decrement
obtained in myeloma patients attaining complete remission
with these aggressive therapies will be significantly greater
than that obtained with current conventional therapies and
will provide a better predictive correlation with survival than
could be demonstrated in this study.
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